Bio

  • Bio
    AncestryDNA clustered 770,000 genomes to find your family’s American immigration story

    AncestryDNA clustered 770,000 genomes to find your family’s American immigration story

    Immigration into the U.S. is a hot political topic right now, but, unless you’re Native American, pretty much everyone here has a family history involving some sort of immigration story. Now AncestryDNA, a consumer genetics subsidiary of the genealogy research site Ancestry.com, wants to help you know more about your family’s immigration journey. To do so, the research… Read More

  • Bio
    Brain science startup NeuroQore hopes its magnets will cure depression

    Brain science startup NeuroQore hopes its magnets will cure depression

    NeuroQore wants to shoot magnetic pulses into your brain to try to treat mental disorders such as anxiety and depression. Most doctors will give patients a number of drugs to treat these disorders, and up to two-thirds of patients won’t respond to their first drug. Another 10 to 30 percent of these same patients will never respond to drugs as treatment. But NeuroQore (not to be… Read More

  • Bio
    The Chan Zuckerberg Biohub invests $50 million in its first 47 research initiatives

    The Chan Zuckerberg Biohub invests $50 million in its first 47 research initiatives

    The Chan Zuckerberg Biohub, a non-profit medical research organization started by Priscilla Chan and Mark Zuckerberg (and not to be confused with the Chan Zuckerberg Initiative, a limited liability corporation to advance human potential) today announced it would be doling out a total of $50 million to its first cohort of disease investigators. The Biohub brings together Bay Area… Read More

  • Bio
    A new lawsuit alleges anti-aging startup Elysium Health hasn’t paid its sole supplier

    A new lawsuit alleges anti-aging startup Elysium Health hasn’t paid its sole supplier

    Chromadex, the sole supplier of anti-aging startup Elysium Health‘s two main product ingredients pterostilbene and Nicotinamide Riboside (NR), is suing the startup for failure to make payments on those ingredients and for breach of a trademark and royalties agreement. According to a document on Chromadex’s website, dated December 29, 2016, Elysium “made… Read More

  • Bio
    Arizona plans to sue Theranos over faulty blood tests

    Arizona plans to sue Theranos over faulty blood tests

    Arizona Attorney General Mark Brnovich is soliciting outside legal counsel to pursue a consumer fraud lawsuit against the beleaguered blood testing startup Theranos, according to a document posted on the state’s procurement website. Brnovich has so far declined to comment on any action, but the document contends Theranos may have defrauded customers in the state and the office is… Read More

  • Bio
    Women’s health startup Celmatix now offers genetic testing for fertility issues

    Women’s health startup Celmatix now offers genetic testing for fertility issues

    Celmatix, a startup with a focus on personalized medicine for women, wants to take some of the mystery out of the science of baby-making with a new type of DNA-based fertility test called Fertilome. Fertilome looks at 49 variants in 32 genes that give you a likelihood or not for inherited disorders such as endometriosis or PCOS to help women determine the best course of action to take based… Read More

  • Bio
    Illumina wants to sequence your whole genome for $100

    Illumina wants to sequence your whole genome for $100

    The first sequencing of the whole human genome in 2003 cost roughly $2.7 billion, but DNA sequencing giant Illumina has now unveiled a new machine that the company says is “expected one day” to order up your whole genome for less than $100. Illumina’s CEO Francis deSouza showed off the machine, called the NovaSeq, onstage at the JP Morgan Healthcare Conference in downtown… Read More

  • Bio
    Theranos slashes another 41 percent of its workforce

    Theranos slashes another 41 percent of its workforce

    Not a week goes by and it seems like we hear more bad news about Silicon Valley’s darling turned cautionary tale Theranos. The latest bit is a whopping 155 layoffs at the company today. The one drop blood test company once worth $9 billion took a quite the tumble from grace after an intense series of investigations from the Centers for Medicare & Medicaid Services and the U.S. Food… Read More

  • Bio
    Grail is raising at least $1 billion to fund its early cancer screening test

    Grail is raising at least $1 billion to fund its early cancer screening test

    The early cancer screening startup Grail plans to raise more than $1 billion in Series B financing, possibly up to $1.8 billion. While the company doesn’t want to name investor names, only mentioning in a release the funding will come “primarily from undisclosed private and strategic investors,” Microsoft co-founder Bill Gates, Amazon founder Jeff Bezos, Google Ventures… Read More

  • Bio
    Silicon Valley Bank predicts a 2017 cure for the healthtech investment doldrums

    Silicon Valley Bank predicts a 2017 cure for the healthtech investment doldrums

    Things are looking up for biotech and health device startups wanting to cash in on VC dollars or go public this year. According to Silicon Valley Bank’s latest report on healthcare investments and exits, a conservative 2016 has set up 2017 for a hearty boom. Though biopharma M&A activity declined slightly last year and IPOs declined more than 30 percent, according to the report… Read More

  • Bio
    Move over Cas9, CRISPR-Cas3 might hold the key to solving the antibiotics crisis

    Move over Cas9, CRISPR-Cas3 might hold the key to solving the antibiotics crisis

    Researchers at North Carolina-based Locus Biosciences think they have a potential cure for antibiotic resistance using CRISPR’s lesser-known Cas3 enzyme. Most of the interest in CRISPR technology centers around the enzyme Cas9, which acts as a type of genetic scissors, allowing scientists to snip out, edit and replace DNA at certain intervals along the genome. However, Cas3 goes beyond… Read More

  1. 1
  2. 2
  3. ...